Let's spread the word about Immunotherapy! Click to share this page with your community.

FUSF Webinar: Cancer Immunotherapy Treatment and Research in a COVID-19 World

In honor of Cancer Immunotherapy Month, the Focused Ultrasound Foundation (FUSF) hosts a special conversation with Jill O’Donnell-Tormey, Ph.D., CEO of the Cancer Research Institute (CRI) and FUSF's Chief Scientific Officer, Jessica Foley, Ph.D.

The Cancer Research Institute is a leader in the field of cancer immunotherapy and important partner to FUSF. Join us to learn more about the lifesaving potential of cancer immunotherapy and the ways that CRI and FUSF are working together to advance exciting research, through a lens of the new COVID-19 environment.

Speakers

Jill O’Donnell-Tormey, Ph.D
Chief Executive Officer and Director of Scientific Affairs

Jill O’Donnell-Tormey, Ph.D., is chief executive officer and director of scientific affairs of the Cancer Research Institute (CRI), a nonprofit organization founded in 1953 that is today the global leader in supporting and coordinating research aimed at harnessing the immune system’s power to conquer all cancers. She joined the organization in 1987, and has been chief executive since 1993. Prior to joining CRI, she served as a research associate in the department of medicine at Cornell University Medical College and as a postdoctoral fellow in the laboratory of cellular physiology and immunology at The Rockefeller University.

Jessica Foley, Ph.D
Chief Scientific Officer

Jessica Foley, Ph.D., joined the Foundation in 2012 after a more than 11-year career in the field of focused ultrasound that spanned academic, industrial and government worlds. As Chief Scientific Officer, Foley guides the strategy, development, and implementation of the scientific and research programs and activities within the Foundation, and aligns these with communications and development efforts. She also leads alliance-building efforts with external stakeholders including (but not limited to) governmental policymakers, regulatory agencies, and disease-specific foundations whose interests are complementary to those of the Foundation. She is a representative and advocate for the Foundation and the focused ultrasound community among a wide variety of stakeholders. Her experience prior to the Foundation included several years with InSightec as the Neuro Projects Manager and Clinical Marketing Manager; Senior Scientist at Medtronic; and serving as a 2011-2012 AAAS Science and Technology.

*Immunotherapy results may vary from patient to patient.

Top